Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West

被引:7
|
作者
Lee, V. H. F. [1 ,2 ]
Seong, J. [3 ]
Yoon, S. M. [4 ]
Wong, T. C. L. [5 ]
Wang, B. [2 ]
Zhang, J. L. [2 ]
Chiang, C. L. [1 ,2 ]
Ho, P. P. Y. [1 ]
Dawson, L. A. [6 ,7 ]
机构
[1] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Univ Hong Kong, Shenzhen Hosp, Clin Oncol Ctr, Shenzhen, Peoples R China
[3] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Radiat Oncol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Liver Ctr, Asan Med Ctr,Dept Radiat Oncol, Seoul, South Korea
[5] Univ Hong Kong, Li Ka Shing Fac Med, Dept Surg, Hong Kong, Peoples R China
[6] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada
[7] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
关键词
Bridging therapy; hepatocellular carcinoma; targeted therapy; transarterial chemoembolisation; transarterial radioembolisation; STEREOTACTIC BODY RADIOTHERAPY; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; RANDOMIZED CONTROLLED-TRIAL; PORTAL-VEIN-THROMBOSIS; RADIATION-THERAPY; DOUBLE-BLIND; PHASE-III; TRANSARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION;
D O I
10.1016/j.clon.2019.06.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatocellular carcinoma (HCC) is a common malignancy worldwide, although its aetiologies vary significantly between the East and the West. About a half of HCC cases present with advanced unresectable HCC at the time of diagnosis, leading to a worse prognosis. Over the past 20 years, the treatment paradigm for advanced unresectable HCC has shifted from an entirely palliative approach to a multidisciplinary treatment, with continuous reassessment and possible repeat treatment attributed to the advent of novel and improved local, regional and systemic therapeutic options, contributed by both the East and the West. An individualised treatment plan should be determined for each patient, as there can be substantial differences in the decision-making and treatment response to the same treatment for different patients and different patient populations. This review provides a summary of the recent advances in management and compares Eastern and Western strategies for HCC. (C) 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:560 / 569
页数:10
相关论文
共 50 条
  • [41] Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview
    Sun, Hui-Chuan
    Zhu, Xiao-Dong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [42] Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
    Henry W. C. Leung
    Chung-Feng Liu
    Agnes L. F. Chan
    Radiation Oncology, 11
  • [43] Checkpoint Inhibition in the Treatment of Unresectable, Advanced Lymphoepithelioma-like Hepatocellular Carcinoma
    Hermel, David J.
    Du, Emma Z.
    Lin, Ray
    Frenette, Catherine T.
    Sigal, Darren S.
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2021, 9 (02) : 265 - 268
  • [44] Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
    Leung, Henry W. C.
    Liu, Chung-Feng
    Chan, Agnes L. F.
    RADIATION ONCOLOGY, 2016, 11
  • [45] Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials - II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma
    Schwartz, JD
    Beutler, AS
    ANTI-CANCER DRUGS, 2004, 15 (05) : 439 - 452
  • [46] Differences between east and west Pacific rainfall systems
    Berg, W
    Kummerow, C
    Morales, CA
    JOURNAL OF CLIMATE, 2002, 15 (24) : 3659 - 3672
  • [47] Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study
    Hull, Diana
    Armstrong, Ceri
    INTERNATIONAL JOURNAL OF PALLIATIVE NURSING, 2010, 16 (05) : 249 - 254
  • [48] MORPHOLOGICAL DIFFERENCES BETWEEN HEPATOCELLULAR-CARCINOMA AND HEPATOCELLULAR CARCINOMA-LIKE LESIONS
    MOTOHASHI, I
    OKUDAIRA, M
    TAKAI, T
    KANEKO, S
    IKEDA, N
    HEPATOLOGY, 1992, 16 (01) : 118 - 126
  • [49] A phase II evaluation of clofazimine plus doxorubicin in advanced, unresectable primary hepatocellular carcinoma
    Falkson, CI
    Falkson, G
    ONCOLOGY, 1999, 57 (03) : 232 - 235
  • [50] Prognostic nomogram for patients with advanced unresectable hepatocellular carcinoma treated with TAE combined with HAIC
    Du, Li-xin
    Sheng, Guo-li
    Shi, An-da
    Li, Kang-shuai
    Liu, Zeng-li
    Tang, Yong-chang
    Liu, Yi
    Zhang, Zong-li
    FRONTIERS IN PHARMACOLOGY, 2024, 15